13299-35-9

Upstream product

• 57988-60-0 4-hydroxy-4-(4-methylphenyl)-piperidine 
• 1195-32-0 1-methyl-4-isopropenylbenzene 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 106-38-7 para-bromotoluene 
• 13314-67-5 1,2,3,6-tetrahydro-4-(4-methylphenyl)-1-(phenylmethyl)-pyridine 

Downstream Products

• 57988-60-0 4-hydroxy-4-(4-methylphenyl)-piperidine 
• 13314-67-5 1,2,3,6-tetrahydro-4-(4-methylphenyl)-1-(phenylmethyl)-pyridine 
• 874352-28-0 N-[1-benzyl-4-(4-methyl-phenyl)-piperidin-4-yl]-acetamide 
• 13314-68-6 C₁₉H₂₁N*ClH 
• 874352-47-3 N-[1-benzyl-4-(4-methyl-phenyl)-piperidin-4-yl]-5-chloro-pentanamide hydrochloride 
• 874352-44-0 N-[1-benzyl-4-(4-methyl-phenyl)-piperidin-4-yl]-4-chloro-butanamide hydrochloride 

Relevant academic research and scientific papers

Synthesis and SAR study of 4-arylpiperidines and 4-aryl-1,2,3,6- tetrahydropyridines as 5-HT2C agonists

A series of substituted 4-arylpiperidines and a smaller family of 4-aryl-1,2,3,6-tetrahydropyridines were synthesized and their biological activity at the 5-HT2C receptor studied to determine whether either series showed noteworthy agonist activity. Structure-activity relationships were developed from the performed receptor binding assays and functional studies, and the results of the analysis are presented herein.

A strategy for isotope containment during radiosynthesis - Devolatilisation of bromobenzene by fluorous-tagging-Ir-catalysed borylation en route to the 4-phenylpiperidine pharmacophore

Syntheses of two 4-phenylpiperidines from bromobenzene have been developed involving anchoring to a fluorous-tag, Ir-catalysed borylation, Pd- and Co-catalysed elaboration then traceless cleavage. Although performed using 'cold' (i.e. unlabelled) bromoben

4-ARYLMORPHOLIN-3-ONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF

The invention relates to compounds corresponding to formula (I): in which: Ar represents a mono- or disubstituted phenyl; R1 represents an unsubstituted or substituted phenyl; R2 represents: a pyridyl; an unsubstituted or substituted phenyl; a benzyl that is unsubstituted or substituted on the phenyl; R2 may moreover represent: a heterocyclic radical; R3 represents various values. The invention also comprises methods for the compounds preparation, formulations comprising them and therapeutic applications thereof.

Studies on the N-dealkylated metabolite of haloperidol

The recent detection of 4-Chlorophenyl-4-piperidinol (CPPO), in rats fed haloperidol and the subsequent demonstration that CPPO produces a freezing action in frogs, has encouraged us to study the structural features that might be responsible for the freezing action. In this study, we have shown that removal of the chloro from the phenyl ring has little effect on the freezing action and the removal of the tertiary alcohol from the piperidine only decreases somewhat the effectiveness of the freezing action. In addition, since replacing the piperidine ring with tetrahydropyridine and piperazine moieties led to compounds without the freezing action, and because 4-phenylpiperidine is the common entity in all the compounds with the freezing action, it is reasonable to suggest that the 4-phenylpiperidine moiety may be responsible for the freezing action observed in CPPO.

New phenylazacycloalkanes

New 4-(phenyl)-piperidine compounds of the general formula I STR1 in which R1 represents hydrogen or lower alkyl, Ph represents a p-phenylene group optionally substituted by lower alkyl, lower alkoxy, nitro and/or halogen, and R2 represents lower alkyl, and pharmaceutically acceptable acid addition salts thereof are useful as antidepressant agents.